Name: CELCUITY INC (CELC) Stock
Brand: CELCUITY INC
Rating: 6.5 (3 reviews)

CELC Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill

CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data

2 days ago - By: Celcuity Inc.

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

2 days ago - By: Benzinga

Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy Application

7 days ago - By: Celcuity Inc.

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

8 days ago - By: Benzinga - Mentions: GWRS IMRX DYAI LEGN ...

Earnings Scheduled For November 12, 2025

15 days ago - By: Investor's Business Daily - Mentions: NVS

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year.

15 days ago - By: Celcuity Inc.

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

16 days ago - By: Celcuity Inc.

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

a month ago - By: Investor's Business Daily - Mentions: LLY

Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results

a month ago - By: Celcuity Inc.

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

a month ago - By: Celcuity Inc.

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

a month ago - By: Celcuity Inc.

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

2 months ago - By: Celcuity Inc.

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

2 months ago - By: Celcuity Inc.

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

3 months ago - By: Celcuity Inc.

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program

3 months ago - By: The Motley Fool

Celcuity Q2 Results Highlight Cash Surge

3 months ago - By: The Motley Fool - Mentions: PFE

Celcuity Expenses Jump 81 Percent

3 months ago - By: Celcuity Inc.

CELCUITY INC (CELC) Stock News

CELC Latest News, Press Relases and Analysis

CELCUITY INC (NASDAQ:CELC) Stock Surges 70% in a Month Following Q3 Earnings Beat and Positive Clinical Data

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Celcuity Analyst No Longer Bullish Despite Breast Cancer Therapy Application

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 12, 2025

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year.

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program

Celcuity Q2 Results Highlight Cash Surge

Celcuity Expenses Jump 81 Percent

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update